LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces the filing of a class action lawsuit on behalf of investors of Biogen, Inc. ("Biogen" or the "Company") (NASDAQ:BIIB) who purchased shares between January 29, 2015 and July 23, 2015, inclusive (the “Class Period”) and have been damaged by the recent declines in the Company’s stock price. Biogen investors have until October 19, 2015 to file a lead plaintiff motion. Investors with losses of over $1,000,000 are encouraged to contact GPM to discuss their legal rights.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. On July 24, 2015 Biogen announced Second Quarter 2015 results and updated its full-year financial guidance decreasing revenue growth to 6% to 8% based largely on revised expectations for the growth of multiple-sclerosis drug tecfidera. The Company announced that sales of tecfidera have slowed on safety concerns following last year's report of the death of a tecfidera patient. On this news, Biogen shares dropped as much as $74.34, or 19.31%, during intraday trading on July 24, 2015, thereby damaging investors.
If you purchased shares of Biogen during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.